NEW YORK (
for $3.6 billion in cash to bolster its presence in the pain relief market, the company said Tuesday.
The deal values King at $14.25 a share, or a 40% premium over King's closing price of $10.15 a share Monday. Pfizer said the acquisition will have no material impact on 2010 earnings but will add approximately 2 cents a share to the drugmaker's estimated 2011 and 2012 earnings.
King is a specialty pharmaceutical company that specializes in pain drugs, including Embeda, an opioid designed with features that make it resistant to abuse and misuse. King earned $1.10 a share in 2009 on total revenue of $1.78 billion but is expected to earn 68 cents a share on $1.48 billion this year, according to Thomson Reuters.
Pfizer said the King acquisition allows the company to expand its current pain offerings, which include Lyrica and Celebrex.
Pfizer shares were down 5 cents to $17.33 in premarket trading Tuesday.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.